| Sign In to gain access to subscriptions and/or personal tools. |
Low-dose radioimmuno-therapy of cancerSchool of Medicine, University of California, San Francisco, San Francisco, CA, USA, pollycove{at}comcast.net
Medical Department, Brookhaven National Laboratory, Upton, NY, USA Four decades of genomic, cellular, animal and human data have shown that low-dose ionizing radiation stimulates positive genomic and cellular responses associated with effective cancer prevention and therapy and increased life span of mammals and humans. 1—8 Nevertheless, this data is questioned because it seems to contradict the well demonstrated linear relation between ionizing radiation dose and damage to DNA without providing a clear mechanistic explanation of how low-dose radiation could produce such beneficial effects. This apparent contradiction is dispelled by current radiobiology that now includes DNA damage both from ionizing radiation and from endogenous metabolic free radicals, and coupled with the biological response to low-dose radiation. Acceptance of current radiobiology would invalidate long established recommendations and regulations of worldwide radiation safety organizations and so destroy the basis of the very expensive existing system of regulation and remediation. More importantly, current radiobiology would facilitate urgently needed clinical trials of low dose radiation (LDR) cancer therapy.
Key Words: lowdose radiation • radiobiology • DNA • mutation • cancer prevention
Human & Experimental Toxicology, Vol. 27, No. 2,
169-175 (2008) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
